The Scottish Aortic Stenosis LongiTudinal Imaging and biomarkeR (SALTIRE) Programme
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Edinburgh
- Trial code
- NCT06047561
- Record updated
- 21 September 2026
- Original description
The goal of this observational study is to understand the processes of what causes and accelerates the disease progress in aortic stenosis and following aortic valve replacement.Read full original descriptionShow less
The goal of this observational study is to understand the processes of what causes and accelerates the disease progress in aortic stenosis and following aortic valve replacement.
Participants will undergo transthoracic echocardiography every 6 months, with annual visits for state-of-the-art scanning techniques including positron-emission tomography combined with computed tomography or magnetic resonance imaging with radiotracers designed to look at disease processes including fibrosis, calcification, inflammation and thrombosis activity.
Inclusion: Male or female aged >50 years; Provision of informed consent prior to any study specific procedures; Patients with bioprosthetic aortic valve replacements, including both surgically and transcatheter implanted valves; Patients with severe aortic stenosis (peak velocity >4.0 m/s; previously recruited patients); Patients with moderate aortic stenosis (peak velocity 3.0-4.0 m/s; new prospectively recruited patients); Patients with mild aortic stenosis (peak velocity 2.5-2.9 m/s; new prospectively recruited patients); Patients with aortic sclerosis (tri-leaflet thickened aortic valve with no obstruction of ventricular outflow); Age and sex-matched healthy volunteers.
Exclusion: Those with an allergy to iodinated contrast; Patients with known Rheumatic Heart Disease; Patients with impaired renal function (eGFR of <30 mL/min/1.73m2); Inability or unwilling to give informed consent; Women who are pregnant or breastfeeding; Patients with known Ochronosis; Patients with known Familial Homozygous Hypercholesterolaemia.